Breadcrumbs

Leukaemia - haematology

Acute lymphoblastic leukaemia

Acute myeloid leukaemia

Acute promyelocytic leukaemia

Chronic lymphocytic leukaemia

Chronic myeloid leukaemia

Hairy cell leukaemia

Myelodysplastic disorders

Acute lymphoblastic leukaemia

Protocol Administration at chemotherapy unit level Review date
Acute lymphoblastic leukaemia BFM 2000 High March 2022
Acute Lymphoblastic leukaemia blinatumomab
High December 2021
Acute lymphoblastic leukaemia dasatinib
Low December 2021
Acute lymphoblastic leukaemia MRD+ blinatumomab
High March 2022
Acute lymphoblastic leukaemia Ph- hyper CVAD part A High September 2022
Acute lymphoblastic leukaemia Ph- hyper CVAD part B High September 2022
Acute lymphoblastic leukaemia Ph- POMP maintenance therapy (mercaptopurine vinCRISTine methotrexate prednisolone) High September 2022
Acute lymphoblastic leukaemia Ph positive GRAAPH-2005
High March 2022
Acute lymphoblastic leukaemia Ph+ hyper CVAD part A and dasatinib
High September 2022
Acute lymphoblastic leukaemia Ph+ hyper CVAD part B and dasatinib
High September 2022
Acute lymphoblastic leukaemia Ph+ maintenance therapy (dasatinib prednisolone vinCRISTine)
High September 2022
Acute lymphoblastic leukaemia Ph+ hyper CVAD part A and imatinib High September 2022
Acute lymphoblastic leukaemia Ph+ hyper CVAD part B and imatinib High September 2022
Acute lymphoblastic leukaemia Ph+ maintenance therapy (imatinib prednisolone vinCRISTine) Medium September 2022
Acute lymphoblastic leukaemia ponatinib
Low March 2021

Acute myeloid leukaemia

Protocol Administration at chemotherapy unit level Review date
Acute myeloid leukaemia azacitidine Low March 2022
Acute myeloid leukaemia low dose cytarabine Low March 2021
Acute myeloid leukaemia consolidation 5-2 ida (cytarabine and IDArubicin) High March 2020
Acute myeloid leukaemia consolidation HiDAC (cytarabine) High March 2020
Acute myeloid leukaemia consolidation IDAC - 1 (cytarabine) High March 2020
Acute myeloid leukaemia FLAG (fludarabine cytarabine and filgrastim) High March 2020
Acute myeloid leukaemia FLAG-Ida (fludarabine cytarabine IDArubicin and filgrastim) High March 2020
Acute myeloid leukaemia induction 7-3 Ida (cytarabine and IDArubicin) High March 2020
Acute myeloid leukaemia consolidation HiDAC (cytarabine) with midostaurin
High March 2022
Acute myeloid leukaemia induction 7-3 (cytarabine and DAUNOrubicin) with midostaurin
High March 2022
Acute myeloid leukaemia midostaurin maintenance
High March 2022

Acute promyelocytic leukaemia

Protocol Administration at chemotherapy unit level Review date
Acute promyelocytic leukaemia APML4 induction High March 2021
Acute promyelocytic leukaemia APML4 consolidation 1 High March 2021
Acute promyelocytic leukaemia APML4 consolidation 2 High March 2021
Acute promyelocytic leukaemia APML4 maintenance Medium March 2021
Acute promyelocytic leukaemia standard risk (chemotherapy free) induction High December 2021
Acute promyelocytic leukaemia standard risk (chemotherapy free) consolidation High December 2021

Chronic lymphocytic leukaemia

Protocol Administration at chemotherapy unit level Review date
Chronic lymphocytic leukaemia FCR (fludarabine CYCLOPHOSPHamide RITUximab) Medium-high March 2021
Chronic lymphocytic leukaemia ibrutinib*
Low
March 2021
Chronic lymphocytic leukaemia idelalisib and rituximab
Medium September 2021
Chronic lymphocytic leukaemia obinutuzumab and chlorambucil Medium March 2021
Chronic lymphocytic leukaemia venetoclax
Medium weeks 1 to 5 of treatment, then low risk March 2021
Chronic lymphocytic leukaemia venetoclax and rituximab
Medium - cycle 1
Low cycle 2 onwards
September 2022
* non-formulary drug

Chronic myeloid leukaemia

Protocol Administration at chemotherapy unit level Review date
Chronic myeloid leukaemia dasatinib Low March 2022
Chronic myeloid leukaemia imatinib
Low
March 2022
Chronic myeloid leukaemia nilotinib
Low March 2022
Chronic myeloid leukaemia ponatinib Low March 2022

Hairy cell leukaemia

Protocol Administration at chemotherapy unit level Review date
Hairy cell leukaemia cladribine Medium March 2022

Myelodysplastic disorders

Protocol Administration at chemotherapy unit level Review date
Myelodysplastic syndrome azacitidine Low March 2022
Primary myelofibrosis ruxolitinib Low September 2022

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Local radiotherapy services required
  4. Non-formulary drug included in the protocol
  5. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.

^ Back to top